Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Patent
1994-10-31
1999-12-28
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
5303872, 530395, A61K 39395, C07K 1642
Patent
active
060078154
ABSTRACT:
The present invention provides vaccines and a means of vaccinating a host so as to prevent or control specific T cell mediated pathologies. The vaccine is composed of anti-idiotypic antibodies which are internal images of a segment of the T cell receptor (TCR) present on the surface of the pathogenic T cells. The vaccine is administered to the host in a manner that induces an immune response directed against the TCR of pathologic T cell. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. Means of determining an appropriate amino acid sequence for such a vaccine are also provided.
REFERENCES:
patent: 4886743 (1989-12-01), Hood et al.
patent: 5612035 (1997-03-01), Howell et al.
Makoto Owhashi and Ellen Heber-Katz, Protection From Experimental Allergic Encephalomyelitis Conferred by a Monoclonal Antibody Directed Against a Shared Idiotype on Rat T Cell Receptors Specific for Myelin Basic Protein, J. Exp. Med. 168:2153-2164 (1988).
Yanagi et al., A Human T-cell-specific cDNA Clone Encodes a Protein Having Extensive Homology to Immunoglobulin Chains, Nature 308:145-149 (1984).
Biddison et al., The Germline Repertoire of T-cell Receptor Beta-chain Genes in Patients with Multiple Sclerosis, Research Immunology 140:212-215 (1989).
Ross et al., Antibodies to Synthetic Peptides Corresponding to Variable-region First-framework Segments of T-cell Receptors, Immunol. Res. 8:81-97 (1989).
Urban et al., Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 54:577-592 (1988).
Lider et al., Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239:181-183 (1988).
Sun et al., Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions. Nature 332:843-845 (1988).
Offner et al., Lymphocyte vaccination against experimental autoimmune encephalomyelitis: evaluation of vaccination protocols. J. Neuroimmunol. 21:13-22 (1989).
Choi et al., Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc. Natl. Acad. Sci. USA 86:8941-8945 (1989).
White et al., The V.beta.-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 56:27-35 (1989).
Pullen et al., Identification of the region of T cell receptor .beta. chain that interacts with the self-superantigen Mls-1.sup.a. Cell 61:1365-1374 (1990).
Janeway, C., Self superantigens? Cell 63:659-661 (1990).
Marrack and Kappler, The staphylococcal enterotoxins and their relatives. Science 248:705-711 (1990).
Schluter et al., Antibodies to synthetic joining segment peptide of the T-cell receptor .beta.-chain: serological cross-reaction between products of T-cell receptor genes, antigen binding T-cell receptors and immunoglobulns. Chem. Abstracts 105(1):464, abstract no. 4767q (1986).
Howell et al., Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246(4930):668-670 (1989).
Vandenbark et al., Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Letters to Nature 341:541-544 (1989).
Patten et al., Structure, expression and divergence of T-cell receptor .beta.-chain variable regions, Nature 312:40-46 (1984).
Ben-Nun et al., Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein. Nature 292:60-61 (1981).
Acha-Orbea et al., Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 54:263-273 (1988).
Burns et al., Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar V .alpha. and V .beta. chain genes even though the major histocompatibility complex of encephalitogenic determinants being recognized are different. J. Exp. Med. 169:27-39 (1989).
Chluba et al., T cell receptor .beta. chain usage in myelin basic protein-specific rat T lymphocytes. Eur. J. Immunol. 19:279-284 (1989).
Wucherpfennig et al., Shared human T cell receptor V.beta. usage to immunodominant regions of myelin basic protein. Science 248:1016-1019 (1990).
Kimura et al., Sequences and repertoire of the human T cell receptor .alpha. and .beta. chain variable region genes in thymocytes. Eur. J. Immunol. 17:375-383 (1987).
Sedgwick, J., Long-term depletion of CD8.sup.+ T cells in vivo in the rat: no observed role for CD8.sup.+ (cytotoxic/ suppressor) cells in the immunoregulation of experimental allergic encephalomyelitis. Eur. J. Immunol. 18:495-502 (1988).
Zamvil et al., Predominant expression of a T cell receptor V.sub..beta. gene subfamily in autoimmune encephalomyelitis, J. Exp. Med. 167:1586-1596 (1988).
Clark et al., "Shared T-cell Receptor Gene Usage in Experimental Allergic Neuritis and Encephalomyelitis" Ann. Neurol. 31:587-592 (1992).
Sellins et al., "Limited T Cell Receptor .beta.-Chain Usage in the Sperm Whale Myoglobin 110-121/E.alpha.d A.beta.d Response by H-2d Congenic Mouse Strains" J. Immunol. 149:2323-2327 (1992).
Lahesmaa et al., "Preferential Usage of T Cell Antigen Receptor V Region Gene Segment V.beta.5.1 by Borrelia burgdorferi Antigen-Reactive T Cell Clones Isolated from a Patient with Lyme Disease" J. Immunol. 150:4125-4135 (1993).
Abe et al., "Selective expansion of T cells expressing T-cell receptor variable regions V.beta.2 and V.beta.8 in Kawasaki disease" Proc. Natl. Acad. Sci. U.S.A. 89:4066-4070 (1992).
Gaur et al., "Requirement for CD8+ Cells in T Cell Receptor Peptide-Induced Clonal Unresponsiveness" Science 259:91-94 (1993).
Gregorian et al., "Immune Regulation by T-Cell Receptor (TCR) V Region Peptide in Experimental Autoimmune Neuritis" FASEB J. 6:A1685 (1992).
Kawano et al., "Trials of Vaccination Against Experimental Autoimmune Uveoretinitis with a T-cell Receptor Peptide" Cancer Eye Research 10:789-795 (1991).
Welch et al., "Regulation of Experimental Allergic Encephalomyelitis" J. Immunol. 125:186-189 (1980).
Infante et al., "Preferential Use of a T Cell Receptor V.beta. Gene By Acetylcholine Receptor Reactive T Cells From Myasthenia Gravis-Susceptible Mice" J. Immunol. 148:3385-3390 (1992).
Paliard et al., "Evidence for the Effects of a Superantigen in Rheumatoid Arthritis" Science 253:325-329 (1991).
Howell et al., "Limited T-cell receptor .beta.-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis" Proc. Natl. Acad. Sci. (U.S.A.) 88:10921-10925 (1991).
Grunewald et al., "Abnormal T-Cell Expansion and V-Gene Usage in Myasthenia Gravis Patients" Scand. J. Immunol. 34:161-168 (1992).
Grunewald et al., "Restricted V.alpha.2.3 gene usage by CD4+ T lymphocytes in bronchoaiveolar lavage fluid from sarcoidosis pateints correlates with HLA-DR3" Eur. J. Immunol. 22:129-135 (1992).
Lee et al., "Common T-cell Receptor Usage in Oligoclonal Lymphocytes derived from Cerebrospinal Fluid and Blood of Patients with Multiple Sclerosis" Ann. Neurol. 29:33-40 (1991).
Posnett et al., "T Cell Antigen Receptor V Gene Usage" J. Clin. Invest. 85:1770-1776 (1990).
Edouard et al., "Evidence for a preferential V.beta. usage by the T cells which adoptively transfer diabetes in NOD mice" Eur. J. Immunol. 23:727-733 (1993).
Smith et al., "Acute Infectious Mononucleosis Stimulates the Selective Expression/Expansion of V.beta.6.1-3 and V.beta.7 T Cells" Blood 81:1521-1526 (1993).
Brostoff Steven W.
Carlo Dennis J.
Howell Mark D.
Cunningham Thomas M.
The Immune Response Corporation
LandOfFree
Anti-idiotype vaccination against diseases resulting from pathog does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-idiotype vaccination against diseases resulting from pathog, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-idiotype vaccination against diseases resulting from pathog will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2380486